PT. RICHMOND, Calif., June 18 /PRNewswire/ -- Transcept
Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President &
Chief Executive Officer, will present at the Jefferies 2nd Annual
Healthcare Conference in New York City on Wednesday, June 25, 2008 at 9:30
AM Eastern Time.
The presentation will be available as a webcast at
http://www.wsw.com/webcast/jeff26/transcept.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to
provide additional uses and enhanced clinical benefits for existing active
agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem
tartrate sublingual lozenge), is a low dose formulation of zolpidem for the
treatment of insomnia in patients who awaken in the middle of the night and
have difficulty returning to sleep. Phase 3 clinical trials have been
completed for Intermezzo(R) and Transcept plans to submit an NDA in the
third quarter of 2008. Transcept is also developing TO-2060, a novel,
fixed-dose combination of olanzapine and ondansetron for the treatment of
dopamine associated psychiatric disorders. For further information, please
visit the company's website at: http://www.transcept.com.
Contacts:
Transcept Pharmaceuticals, Inc. The Ruth Group
Michael Gill Investors/Media
Director of Communications Stephanie Carrington/Jason Rando
(510) 215-3575 (646) 536-7017 / 7025
mgill@transcept.com scarrington@theruthgroup.com
jrando@theruthgroup.com
SOURCE Transcept Pharmaceuticals, Inc.
 back to top
Related links:
http://www.transcept.com
CONTACT:
Michael Gill, Director of Communications,
Transcept Pharmaceuticals, Inc., +1-510-215-3575,
mgill@transcept.com; Investors-Media: Stephanie Carrington,
+1-646-536-7017, scarrington@theruthgroup.com, or Jason Rando,
+1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group
for Transcept Pharmaceuticals, Inc.
|
